Ewis S A, Abdel-Rahman M S
Department of Pharmacology/Toxicology, New Jersey Medical School, Newark, USA.
J Appl Toxicol. 1995 Sep-Oct;15(5):387-90. doi: 10.1002/jat.2550150508.
Recently there has been growing interest in magnesium deficiency and its correlation with coronary artery disease, chronic complications of diabetes mellitus and antioxidant enzyme activity. Hypomagnesemia is a common association of diabetes mellitus, and the blood glutathione (GSH) level is significantly lower in both conditions. Metformin (Met), 'an oral antihyperglycemic drug' frequently used in the management of diabetes mellitus outside the USA, has been shown to have an insulin-like action. The purpose of this study was to investigate the effect of oral administration of Met (60 mg kg(-1)) for 14 days on GSH and magnesium levels in blood, liver and heart of normal and streptozotocin-induced diabetic Wistar rats. Diabetes was induced by an i.p. injection of streptozotocin (60 mg kg(-1)). Our results showed that Met did not affect fasting serum glucose concentration in non-diabetic animals but reduced it significantly in diabetic animals. Serum and liver magnesium levels were significantly decreased in the untreated diabetic group compared with the normal group. Treatment with Met improved liver magnesium concentration in the diabetic group only. It has no effect on serum magnesium in diabetic or non-diabetic rats. Heart magnesium levels showed non-significant changes in all groups. In diabetic animals a significant decrease of GSH in both blood and liver was observed. Treatment with Met increased these levels significantly, with a similar effect on GSH levels in non-diabetic rats. There were no significant changes in heart GSH levels in any of the groups. This study demonstrates that oral Met therapy improves the altered levels of magnesium and GSH in diabetic rats.
最近，人们对镁缺乏及其与冠状动脉疾病、糖尿病慢性并发症和抗氧化酶活性的相关性越来越感兴趣。低镁血症是糖尿病常见的伴发现象，在这两种情况下血液中的谷胱甘肽（GSH）水平均显著降低。二甲双胍（Met）是一种在美国以外常用于治疗糖尿病的“口服降糖药”，已被证明具有胰岛素样作用。本研究的目的是调查连续14天口服Met（60 mg kg⁻¹）对正常和链脲佐菌素诱导的糖尿病Wistar大鼠血液、肝脏和心脏中GSH和镁水平的影响。通过腹腔注射链脲佐菌素（60 mg kg⁻¹）诱导糖尿病。我们的结果表明，Met对非糖尿病动物的空腹血糖浓度没有影响，但在糖尿病动物中显著降低了空腹血糖浓度。与正常组相比，未治疗的糖尿病组血清和肝脏中的镁水平显著降低。Met治疗仅改善了糖尿病组肝脏中的镁浓度。它对糖尿病或非糖尿病大鼠的血清镁没有影响。所有组中心脏中的镁水平均无显著变化。在糖尿病动物中，观察到血液和肝脏中的GSH均显著降低。Met治疗显著提高了这些水平，对非糖尿病大鼠的GSH水平也有类似影响。任何组中心脏中的GSH水平均无显著变化。本研究表明，口服Met疗法可改善糖尿病大鼠体内镁和GSH的异常水平。
